Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jared Heaton

MOHS-Micrographic Surgery Bountiful, UT Doctor of Osteopathy

NPI 1457666562 CMS profile 156584

320 W 500 S Ste 210, Bountiful, UT 84010

Open in the dashboard

General payments

$3,082

179 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jared Heaton of Bountiful, UT is reported in the CMS Open Payments database as having received $3,082 across 179 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $130 7
2024 General $442 13
2023 General $114 5
2022 General $217 13
2021 General $472 28
2020 General $520 28
2019 General $1,187 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jared Heaton
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Jared Heaton were reported at $130. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Jared Heaton MOHS-Micrographic Surgery median Middle half National median
2019 $1,187 $316 $106–$785 $163
2020 $520 $162 $68–$412 $114
2021 $472 $243 $87–$654 $132
2022 $217 $300 $102–$887 $149
2023 $114 $364 $125–$1,010 $160
2024 $442 $445 $142–$1,108 $164
2025 $130 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $479 24 payments
  2. Novartis Pharmaceuticals Corporation $376 24 payments
  3. Allergan Inc. $348 32 payments
  4. Ortho Dermatologics, a division of Bausch Health US, LLC $240 9 payments
  5. Pfizer Inc. $208 20 payments
  6. Lilly USA, LLC $182 10 payments
  7. Janssen Biotech, Inc. $156 5 payments
  8. Incyte Corporation $135 3 payments
  9. PruGen, Inc. Pharmaceuticals $129 6 payments
  10. Sun Pharmaceutical Industries Inc. $127 7 payments
  11. Other $702 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,973 177 payments
  2. Education $99 1 payment
  3. Entertainment $10 1 payment
Products named General payments · program years 2019–2025
  1. SKYRIZI $355 17 payments
  2. BOTOX COSMETIC $299 29 payments
  3. EUCRISA $208 20 payments
  4. DUOBRII $190 5 payments
  5. COSENTYX Immunology $167 11 payments
  6. BRYHALI $160 3 payments
  7. TREMFYA $156 5 payments
  8. TALTZ $154 9 payments
  9. COSENTYX Dermatology $150 10 payments
  10. SILIQ $140 1 payment
  11. Other $1,621 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

533

Median for Dermatology: 534

Drug cost

$7,994

Median for Dermatology: $67,151

Branded share of claims

2.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mupirocin Generic 172 $1,551
Clobetasol Propionate Generic 45 $1,374
Fluorouracil Generic 14 $1,132
Cephalexin Generic 124 $922
Metronidazole Generic 12 $918
Triamcinolone Acetonide Generic 50 $730
Minoxidil Generic 40 $550
Ketoconazole Generic 32 $471
Hydrocortisone Generic 18 $146
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $109

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$304,666

Of which drugs: $7,655

Medicare patients

368

Average age 76

Services billed

3,605

158 women, 210 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 41%
Diabetes 24%
Chronic kidney disease 24%
Ischemic heart disease 22%
Depression 18%
Atrial fibrillation 17%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 17 $12

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPZELURA
  • Incyte Corporation $135
$135 — —
SKYRIZI
  • AbbVie, Inc. $105
$105 — —
Bimzelx
  • UCB, Inc. $42
$42 — —
TREMFYA
  • Janssen Biotech, Inc. $40
$40 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

179 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record